CDSCO granted marketing authorisation to Qdenga, Takeda's live-attenuated tetravalent dengue vaccine — the first dengue vaccine approved in India.
It is approved for people aged 4 to 60 in two 0.5 ml subcutaneous doses given three months apart (0 and 3 months).
Qdenga is made by Takeda GmbH, Germany, and will be imported by Takeda Biopharmaceuticals India; a pivotal Phase III study was run in Indians aged 4-60.
The vaccine is approved in 42 countries including the EU and UK, carries WHO prequalification, and over 24 million doses have been distributed worldwide.
The vaccine adds to the vector control, surveillance and case management already run under the National Vector Borne Disease Control Programme.
A weakened dengue virus type-2 serves as a backbone; genes for surface proteins of the other serotypes are engineered into it, so one vaccine presents all four serotypes. It is grown in Vero cells, contains GMOs and is supplied freeze-dried.
Simple Analogy: One chassis carrying four different number plates.
| Aspect | Qdenga (TAK-003) | Dengvaxia (CYD-TDV) | DengiAll |
|---|---|---|---|
| Developer | Takeda (Japan) | Sanofi Pasteur (France) | Panacea Biotec with ICMR (India) |
| Doses | 2 doses, 3 months apart | 3 doses at 0/6/12 months | Single dose |
| First registration | Approved in India on 21 Jul 2026 (India's first) | Mexico, December 2015 (world's first) | Phase III enrolment of 10,335 completed Jan 2026 |
| WHO prequalification | Yes — 10 May 2024, the second dengue vaccine prequalified | Yes — the first prequalified | Not yet |
Central drug regulator under the Drugs and Cosmetics Act, 1940; approves new drugs, vaccines and clinical trials; six zonal offices and seven laboratories
Runs the National Vector Borne Disease Control Programme for six diseases — malaria, dengue, chikungunya, Japanese encephalitis, kala-azar and lymphatic filariasis
WHO's quality, safety and efficacy check that lets UN agencies such as UNICEF procure a vaccine
Parent law under which CDSCO evaluated quality, safety and efficacy and granted the marketing authorisation
Notified 19 March 2019 under the 1940 Act; replaced Part XA and Schedule Y of the 1945 Rules; governs approval of new drugs and trials, with a 30-day clock for domestic trial applications
Four serotypes, DENV-1 to DENV-4; a tetravalent vaccine targets all four
Main vector; bites chiefly by day, mostly early morning and late afternoon; Aedes albopictus also transmits dengue
Aedes aegypti also carries chikungunya, Zika and yellow fever viruses
Single-dose live-attenuated vaccine from Butantan Institute, São Paulo, approved by Brazil's regulator ANVISA
GS Paper 3 > Science & Technology > Biotechnology; GS Paper 2 > Health
General Awareness > Science > Diseases and Vaccines
Current Affairs > Health
Which one of the following statements is not correct?
Answer: Hepatitis B, unlike Hepatitis C, does not have a vaccine.
A vaccine protecting against four strains or serotypes of a pathogen
Contains a weakened live pathogen that triggers immunity without causing disease
WHO assessment of a vaccine's quality, safety and efficacy that enables UN procurement
A cell line from African green monkey kidney used to grow viral vaccines